SaMD and regulated digital health companies can secure authorization, complete pilots, and sign customers without reaching repeatable, profitable use.
Vahana Labs helps leadership teams identify the decisions blocking market entry and sequence them before they become expensive commitments.
Inside regulated health technology
Clinical AI, digital health, connected products
Work involving Gilead and Moderna programs
Product, regulatory, evidence, privacy, commercialization
Regulatory strategy shapes the claims the company can make. Claims determine the evidence required. Evidence influences who will buy. The buyer determines payment, workflow, implementation, and contracting.
When these decisions are managed separately, the company accumulates approvals, pilots, integrations, and conversations without building commercial momentum.
The company keeps moving forward.
But each new indication, buyer, or market still feels like starting over.
Where should the next indication, buyer, market, or deployment be faster and less expensive than the last — and why isn’t it?
Commercialization is not a linear funnel. It is a connected operating system.
Choose the indication, buyer, use case, channel, and payment model that can support a viable business.
A large market is not necessarily an enterable market. The opportunity has to align with buyer urgency, evidence burden, regulatory constraints, workflow readiness, implementation capacity, and economic value.
Connect regulatory strategy, claims, evidence, reimbursement, buyer requirements, economics, and contractual obligations.
A product can be clinically valuable and authorized without being buyable. Evidence may satisfy the regulator but not the buyer. A reimbursement pathway may exist without a viable business model. Sales promises may exceed implementation capacity.
Design pilots, procurement, workflow integration, implementation, and adoption around the decision that has to follow.
Many companies can secure champions and pilots. Far fewer can convert those pilots into contracts, and those contracts into sustained use.
Make each indication, customer, and deployment improve the economics and speed of the next.
Evidence, integrations, buyer materials, contract positions, implementation assets, and postmarket learning should become reusable capabilities. When they do not, complexity grows as quickly as revenue.
PACE is the shorthand. Underneath it, engagements use the SaMD Commercialization Leverage Map to locate the constraint and sequence the work.
If more than two of these are familiar, the constraint is probably not where the organization is looking.
These are rarely isolated regulatory, commercial, product, or implementation failures. They occur at the seams between functions.
A viable contracting and payment model, not temporary pilot funding or unsustainable services.
Embedded in normal clinical or operational workflow, not dependent on exceptional effort or one champion.
Claims appropriate for the product, population, buyer, and use context.
Actively influencing care or operations, not merely authorized, contracted, integrated, or technically available.
A focused engagement for SaMD, DTx, diagnostic, and AI-enabled clinical companies facing a material market-entry decision in the next 30 to 90 days.
Arvita Tripati has nearly two decades of experience across SaMD, diagnostics, clinical AI, product, regulatory strategy, privacy, evidence, and enterprise adoption.
Her work has included FDA-regulated AI-enabled products, entry into NHS and VA environments, and scaling regulated clinical platforms involving organizations such as Gilead and Moderna.
The advantage is not another isolated functional opinion.
It is seeing how the decisions interact before they become expensive constraints.
More on the backgroundNot regulatory submission writing, outsourced lead generation, coding research, or a broad market landscape with no decision attached.
You do not need another generic market-entry plan.
You need to know what stands between the product and cleanly paid, routine, evidence-supported use.
Pressure test your market-entry plan →